VAUGHAN, Ontario / Mar 26, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 30, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.
Conference Call Details
Date: | Wednesday, April 30, 2025 | ||
Time: | 8 a.m. ET | ||
Webcast: | |||
Participant Event Dial-in: | +1 (888) 506-0062 (North America) +1 (973) 528-0011 (International) | ||
Participant Access Code: | 810276 | ||
Replay Dial-in: | +1 (877) 481-4010 (North America) +1 (919) 882-2331 (International) | ||
Replay Passcode: | 51713 (replay available until May 14, 2025) |
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.
© 2025 Bausch + Lomb.
| Last Trade: | US$15.63 |
| Daily Change: | -0.12 -0.76 |
| Daily Volume: | 388,282 |
| Market Cap: | US$5.530B |
September 11, 2025 September 09, 2025 September 08, 2025 August 18, 2025 July 30, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
